Knight Therapeutics Inc.

TSX:GUD 주식 보고서

시가총액: CA$550.0m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Knight Therapeutics 관리

관리 기준 확인 3/4

Knight Therapeutics' CEO는 Samira Sakhia, Aug2016 에 임명되었습니다 의 임기는 7.83 년입니다. 총 연간 보상은 CA$ 1.17M, 40.1% 로 구성됩니다. 40.1% 급여 및 59.9% 보너스(회사 주식 및 옵션 포함). 는 CA$ 1.37M 가치에 해당하는 회사 주식의 0.25% 직접 소유합니다. 1.37M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 7.8 년입니다.

주요 정보

Samira Sakhia

최고 경영자

CA$1.2m

총 보상

CEO 급여 비율40.1%
CEO 임기7.8yrs
CEO 소유권0.3%
경영진 평균 재임 기간3yrs
이사회 평균 재임 기간7.8yrs

최근 관리 업데이트

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

CEO 보상 분석

Samira Sakhia 의 보수는 Knight Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-CA$17m

Dec 31 2023n/an/a

-CA$17m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$16m

Mar 31 2023n/an/a

-CA$15m

Dec 31 2022CA$1mCA$468k

-CA$30m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$33m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$1mCA$401k

CA$16m

Sep 30 2021n/an/a

CA$32m

Jun 30 2021n/an/a

CA$59m

Mar 31 2021n/an/a

CA$47m

Dec 31 2020CA$688kCA$298k

CA$42m

Sep 30 2020n/an/a

CA$27m

Jun 30 2020n/an/a

CA$6m

Mar 31 2020n/an/a

CA$8m

Dec 31 2019CA$987kCA$287k

CA$15m

Sep 30 2019n/an/a

CA$21m

Jun 30 2019n/an/a

CA$37m

Mar 31 2019n/an/a

CA$22m

Dec 31 2018CA$787kCA$267k

CA$24m

Sep 30 2018n/an/a

CA$31m

Jun 30 2018n/an/a

CA$22m

Mar 31 2018n/an/a

CA$18m

Dec 31 2017CA$438kCA$263k

CA$17m

보상 대 시장: Samira 의 총 보상 ($USD 851.09K ) Canadian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.24M ).

보상과 수익: 회사가 수익성이 없는 동안 Samira 의 보상이 증가했습니다.

CEO

Samira Sakhia (56 yo)

7.8yrs

테뉴어

CA$1,166,767

보상

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

리더십 팀

이름위치테뉴어보상소유권
Jonathan Goodman
Executive Chairman11.4yrsCA$438.93k21.49%
CA$ 118.2m
Samira Sakhia
President7.8yrsCA$1.17m0.25%
CA$ 1.4m
Arvind Utchanah
Chief Financial Officer4.3yrsCA$801.68k0.040%
CA$ 221.3k
Amal Khouri
Chief Business Officer3.3yrsCA$719.09k0.15%
CA$ 840.7k
Jeff Martens
Global Vice President of Commercial3.7yrsCA$534.15k데이터 없음
Stephani Saverio
Vice President of Business Development3.2yrsCA$550.38k데이터 없음
Leopoldo Bosano
Vice-President of Manufacturing & Operations2.3yrs데이터 없음데이터 없음
Monica Percario
Global Vice President of Scientific Affairsno data데이터 없음데이터 없음
Henrique Dias
Global Director of Marketing1.4yrs데이터 없음0.0021%
CA$ 11.4k
Susan Emblem
Global Vice President of Human Resources2.8yrs데이터 없음0.019%
CA$ 105.0k
Melanie Groleau
Global Vice President of Medical & Clinicalless than a year데이터 없음데이터 없음

3.0yrs

평균 재임 기간

경험이 풍부한 관리: GUD 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Jonathan Goodman
Executive Chairman11.4yrsCA$438.93k21.49%
CA$ 118.2m
Samira Sakhia
President7.8yrsCA$1.17m0.25%
CA$ 1.4m
James Gale
Independent Lead Director11.4yrsCA$155.00k0.052%
CA$ 284.6k
Robert Lande
Independent Director10.4yrsCA$133.83k0.24%
CA$ 1.3m
Nicolas Sujoy
Independent Director4yrsCA$125.58k0.012%
CA$ 64.1k
Janice Murray
Independent Director4yrsCA$122.50k0.0084%
CA$ 46.1k
Michael Tremblay
Independent Director5.1yrsCA$115.00k0.0020%
CA$ 10.8k

7.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: GUD 의 이사회는 경험(평균 재직 기간 7.8 년)으로 간주됩니다.